| 摘要: |
| [摘要] 目的：探究不同剂量甲泼尼龙琥珀酸钠治疗小儿重症支原体肺炎的疗效及安全性。方法：选择2015年1月至2017年1月我院诊治的小儿重症支原体肺炎62例患儿，按照入院先后顺序分为对照组和研究组各31例，对照组在常规治疗基础上予以常规剂量2 mg/（kg﹒d）的甲泼尼龙琥珀酸钠治疗，研究组在常规治疗基础上予以冲击剂量20 mg/（kg﹒d）的甲泼尼龙琥珀酸钠治疗，比较两组临床疗效及临床症状改善时间。结果：研究组总有效率为96.77%，显著高于对照组的77.42%，差异有统计学意义（χ2=5.167，P<0.05）。治疗后，研究组的退热时间、咳嗽减轻时间、肺部啰音消失时间、胸片恢复时间均明显缩短，与对照组比较差异有统计学意义（P<0.05）。治疗后两组患儿CRP水平均较治疗前下降，差异有统计学意义（P均<0.01）。治疗前两组患儿组间比较差异无统计学意义（P>0.05），治疗后两组患儿比较差异有统计学意义（P<0.05）。两组患儿均未见明显不良反应（P>0.05）。结论：小儿重症支原体肺炎予以冲击剂量甲泼尼龙琥珀酸钠治疗，可缩短患儿各种临床症状改善时间，减轻炎症反应，提升临床总有效率，安全性好。 |
| 关键词: 甲泼尼龙琥珀酸钠 小儿 重症 支原体肺炎 安全性 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2019.02.010 |
|
| 基金项目: |
|
| Different Doses of Methylprednisolone Sodium Succinate in the Treatment of Children with Severe Mycoplasma Pneumoniae Pneumonia |
| Zhao Hongying |
| (The First Affiliated Hospital of Dali University, Yunnan Dali 671000, China) |
| Abstract: |
| [Abstract] Objective: To explore the efficacy and safety of different doses of methylprednisolone sodium succinate in the treatment of children with severe Mycoplasma pneumoniae pneumonia (MPP). Methods: Totally 62 children with severe MPP admitted into our hospital from Jan. 2015 to Jan. 2017 were extracted to be divided into the control group and the experimental group via the admission sequence, with 31 cases in each group. The control group was treated with methylprednisolone sodium succinate at 2 mg/(kg d) on the basis of the conventional treatment, and the experimental group received methylprednisolone sodium succinate at 20 mg/(kg d) on the basis of the conventional treatment. The clinical efficacy and improvement time of clinical symptoms of the two groups were compared. Results: The total effective rate of the experimental group was 96.77%, significantly higher than that of the control group 77.42%, with statistically significant difference (χ2=5.167, P<0.05). After treatment, the clearance time of fever, relieving time of cough, disappearance time of lung rales and recovery time of chest radiography in the experimental group were all significantly shortened, with statistically significant differences compared with the control group (P<0.05). Before treatment, there was no statistically significant difference in the CRP levels between two groups (P>0.05); after treatment, the CRP levels in both groups were lower than those before treatment,wirh statistically significant difference(P<0.01), and the difference was statistically significant between two groups after treatment (P<0.05). No significant adverse drug reactions were observed in both groups (P>0.05). Conclusion: Large dose of methylprednisolone sodium succinate in the treatment of children with severe MPP can shorten the improvement time of clinical symptoms in children, reduce the inflammatory reactions and improve the overall clinical efficiency with higher safety. |
| Key words: methylprednisolone sodium succinate children severe Mycoplasma pneumoniae pneumonia safety |
